The study will also investigate the response of individuals with A-T to TZDs. Studies of the mouse model of A-T has demonstrated response to the TZD pioglitazone,. Of note, pioglitazone is now used off-licence in non-diabetics for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) [6, 7], therefore we know it is safe for use in a non-diabetic cohort.